6-methyl-2-(4'-methoxy)phenyl-4-quinolone | 457932-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-methyl-2-(4'-methoxy)phenyl-4-quinolone
• 英文别名: 6-methyl-2-(4-methoxyphenyl)quinoline-1H-4-one；2-(4-methoxyphenyl)-6-methyl-1H-quinolin-4-one
• CAS: 457932-28-4
• 化学式: C₁₇H₁₅NO₂
• 分子量: 265.312
• InChiKey: WRDZZSZWVPULSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-ethoxy-6-methyl-2-(4'-methoxy)phenylflavylium perchlorate 在 ammonium hydroxide 作用下， 反应 3.0h， 以88%的产率得到6-methyl-2-(4'-methoxy)phenyl-4-quinolone
  参考文献：
  名称：

  通过4-乙氧基黄酮盐方便地合成1,6,7,8-取代的2-（3'，4'-取代的苯基）-4-喹诺酮

  摘要：

  在70％高氯酸在原甲酸乙酯中将2-羟基苯乙酮与苯甲醛缩合，得到相应的4-乙氧基高氯酸黄酮，将其用氨水或甲胺溶液处理，得到1,6,7,8-取代的2-（3 ′，4′-取代的苯基）-4-喹诺酮，收率中等至良好。

  DOI：

  10.1002/jhet.5570360513

文献信息

• Chromane derivatives, process for their preparation and their use as antitumor agents
  申请人：——

  公开号：US20040116497A1

  公开（公告）日：2004-06-17

  Compounds which are chromane derivatives of formula (I), pharmaceutically acceptable salts, process for their preparation and pharmaceutical compositions thereof are disclosed, as set forth in the specification; these compounds are useful in therapy in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

  本发明公开了式(I)的香豆素衍生物化合物、药学上可接受的盐、其制备方法以及制备的药物组合物。这些化合物在治疗与改变的细胞周期依赖性激酶活性相关的细胞增殖性疾病，例如癌症中具有应用价值。
• CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1379524A2

  公开（公告）日：2004-01-14
• [EN] CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE CHROMANE, PROCEDE DE PREPARATION ET D'UTILISATION DE CES DERIVES EN TANT QU'AGENTS ANTITUMORAUX
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2002070515A2

  公开（公告）日：2002-09-12

  Compounds which are chromane derivatives of formula (I), pharmaceutically acceptable salts, process for their preparation and pharmaceutical compositions thereof are disclosed, as set forth in the specification; these compounds are useful in therapy in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.